ATE407132T1 - Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen - Google Patents

Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen

Info

Publication number: ATE407132T1
Authority: AT; Austria
Prior art keywords: jnk; kinases; inhibitors; jun; compounds
Prior art date: 2000-12-05

Application number

AT01989898T

Other languages

English (en)

Inventor

Mark Ledeboer

Francesco Salituro

Young-Choon Moon

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-05

Filing date

2001-12-05

Publication date

2008-09-15

2001-12-05 Application filed by Vertex Pharma filed Critical Vertex Pharma

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE407132T1 publication Critical patent/ATE407132T1/de

Links

108091000080 Phosphotransferase Proteins 0.000 title 1
102000001253 Protein Kinase Human genes 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
102000020233 phosphotransferase Human genes 0.000 title 1
108060006633 protein kinase Proteins 0.000 title 1
108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 abstract 3
102000019145 JUN kinase activity proteins Human genes 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
102000001708 Protein Isoforms Human genes 0.000 abstract 2
108010029485 Protein Isoforms Proteins 0.000 abstract 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 abstract 1
101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 abstract 1
101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
239000012825 JNK inhibitor Substances 0.000 abstract 1
102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 abstract 1
102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 abstract 1
102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 abstract 1
102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 abstract 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)

AT01989898T 2000-12-05 2001-12-05 Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen ATE407132T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25140900P	2000-12-05	2000-12-05

Publications (1)

Publication Number	Publication Date
ATE407132T1 true ATE407132T1 (de)	2008-09-15

Family

ID=22951847

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01989898T ATE407132T1 (de)	2000-12-05	2001-12-05	Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen

Country Status (10)

Country	Link
US (1)	US20020111353A1 (de)
EP (1)	EP1343781B1 (de)
JP (2)	JP4377583B2 (de)
AT (1)	ATE407132T1 (de)
AU (1)	AU2002228783A1 (de)
CA (1)	CA2430539C (de)
DE (1)	DE60135676D1 (de)
ES (1)	ES2307667T3 (de)
MX (1)	MXPA03005001A (de)
WO (1)	WO2002046184A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4316893B2 (ja)	2001-05-16	2009-08-19	バーテックスファーマシューティカルズインコーポレイテッド	Ｓｒｃおよび他のプロテインキナーゼのインヒビター
US7018999B2 (en)	2001-05-16	2006-03-28	Cephalon, Inc.	Methods for the treatment and prevention of pain
US7115617B2 (en)	2001-08-22	2006-10-03	Amgen Inc.	Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en)	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
ES2268127T3 (es) *	2001-12-07	2007-03-16	Applied Research Systems Ars Holding N.V.	Derivados de benzazol para el tratamiento de esclerodermia.
ATE357256T1 (de) *	2002-01-31	2007-04-15	Daiichi Seiyaku Co	Arzneimittel zur behandlung von störungen des zirkadianen rhythmus
US6677337B2 (en) *	2002-03-19	2004-01-13	The Procter & Gamble Company	1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
GB0215844D0 (en) *	2002-07-09	2002-08-14	Novartis Ag	Organic compounds
SE0203654D0 (sv) *	2002-12-09	2002-12-09	Astrazeneca Ab	New compounds
DE602005020611D1 (de) *	2004-04-28	2010-05-27	Vertex Pharma	Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
WO2005118543A1 (ja) *	2004-06-03	2005-12-15	Ono Pharmaceutical Co., Ltd.	キナーゼ阻害薬およびその用途
US20060223807A1 (en)	2005-03-29	2006-10-05	University Of Massachusetts Medical School, A Massachusetts Corporation	Therapeutic methods for type I diabetes
US7713987B2 (en)	2005-12-06	2010-05-11	Rigel Pharmaceuticals, Inc.	Pyrimidine-2,4-diamines and their uses
TWI630207B (zh)	2005-12-13	2018-07-21	英塞特控股公司	作為傑納斯激酶（ＪＡＮＵＳＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
WO2007129195A2 (en) *	2006-05-04	2007-11-15	Pfizer Products Inc.	4-pyrimidine-5-amino-pyrazole compounds
WO2007141224A2 (en) *	2006-06-02	2007-12-13	Laboratoires Serono Sa	Jnk inhibitors for treatment of skin diseases
ES2301380B1 (es)	2006-08-09	2009-06-08	Laboratorios Almirall S.A.	Nuevos derivados de 1,7-naftiridina.
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es)	2007-04-26	2010-09-23	Laboratorios Almirall S.A.	Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP3070090B1 (de)	2007-06-13	2018-12-12	Incyte Holdings Corporation	Verwendung der salze des janus-kinasehemmers (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropannitril
ES2569528T3 (es)	2007-11-16	2016-05-11	Incyte Holdings Corporation	4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
CA2707989A1 (en)	2007-12-07	2009-06-11	Novartis Ag	Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
WO2009103032A1 (en)	2008-02-15	2009-08-20	Rigel Pharmaceuticals, Inc.	Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
EP2108641A1 (de)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	Neue substituierte Spiro[Cycloalkyl-1,3'-indo]-2'(1'H)-on-Derivate und ihre Verwendung als p38 mitogen-activated Kinase Inhibitoren
EP2113503A1 (de)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	Neue substituierte Indolin-2-on- Derivate und ihre Verwendung als p39 mitogen-activated Kinase Inhibitoren
EP3643312A1 (de)	2009-05-22	2020-04-29	Incyte Holdings Corporation	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- oder heptannitril als jak-inhibitoren
AR076794A1 (es)	2009-05-22	2011-07-06	Incyte Corp	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
AR078012A1 (es)	2009-09-01	2011-10-05	Incyte Corp	Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EP2322176A1 (de)	2009-11-11	2011-05-18	Almirall, S.A.	Neue 7-Phenyl-[1,2,4]triazol[4,3-a]pyridin-3(2H)on-Derivate
EP3050882B1 (de)	2010-03-10	2018-01-31	Incyte Holdings Corporation	Piperidin-4-yl-azetidin-derivate als jak1-inhibitoren
SG10201503983QA (en)	2010-05-21	2015-06-29	Incyte Corp	Topical Formulation for a JAK Inhibitor
HUE029196T2 (en)	2010-06-04	2017-02-28	Hoffmann La Roche	Aminoprimidine derivatives as LRRK2 modulators
SG189043A1 (en)	2010-11-10	2013-05-31	Hoffmann La Roche	Pyrazole aminopyrimidine derivatives as lrrk2 modulators
CN103415515B (zh)	2010-11-19	2015-08-26	因塞特公司	作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
US9034884B2 (en)	2010-11-19	2015-05-19	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
BR112013015774A2 (pt)	2010-12-01	2018-05-22	Nissan Chemical Industries Ltd	compostos de pirazol tendo efeito terapêutico sobre mieloma múltiplo.
PE20140832A1 (es)	2011-06-20	2014-07-14	Incyte Corp	Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
IN2014KN02601A (de)	2012-04-24	2015-05-08	Vertex Pharma
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PL2919766T3 (pl)	2012-11-15	2021-10-04	Incyte Holdings Corporation	Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
CN105189509B (zh)	2013-03-06	2017-12-19	因赛特公司	用于制备jak抑制剂的方法及中间体
SMT202100687T1 (it)	2013-03-12	2022-01-10	Vertex Pharma	Inibitori della dna-pk
SG10201912203XA (en)	2013-08-07	2020-02-27	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
ES2705342T3 (es)	2013-10-17	2019-03-22	Vertex Pharma	Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016105491A1 (en)	2014-12-23	2016-06-30	Fgh Biotech	Compositions of fatostatin based heterocyclic compounds and uses thereof
HRP20211949T1 (hr) *	2015-08-04	2022-03-18	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Derivat pirazol primidina i njegove uporabe
WO2017190086A1 (en)	2016-04-29	2017-11-02	Fgh Biotech, Inc.	Di-substituted pyrazole compounds for the treatment of diseases
WO2018049080A1 (en)	2016-09-07	2018-03-15	Fgh Biotech, Inc.	Di-substituted pyrazole compounds for the treatment of diseases
EP3518931A4 (de)	2016-09-27	2020-05-13	Vertex Pharmaceuticals Incorporated	Verfahren zur behandlung von krebs mit einer kombination aus dna-schädigenden substanzen und dna-pk-inhibitoren
WO2019110139A1 (en) *	2017-12-05	2019-06-13	Eth Zurich	New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
WO2019113487A1 (en)	2017-12-08	2019-06-13	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3746429B1 (de)	2018-01-30	2022-03-09	Incyte Corporation	Verfahren zur herstellung von (1-(3-fluor-2-trifluormethyl)isonicotinyl)piperidin-4-on)
PT3773593T (pt)	2018-03-30	2024-06-25	Incyte Corp	Tratamento da hidradenite supurativa com inibidores de jak
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
JP7186874B2 (ja) *	2018-10-26	2022-12-09	アーリーンファーマシューティカルズエルエルシー	ピラゾリル化合物およびその使用方法
US11384083B2 (en)	2019-02-15	2022-07-12	Incyte Corporation	Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en)	2019-03-05	2022-10-18	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en)	2019-03-29	2020-10-08	Incyte Corporation	Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en)	2019-05-01	2022-09-13	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
DK3985000T3 (da) *	2019-06-28	2024-12-16	Chengdu Zenitar Biomedical Tech Co Ltd	2,4-disubstituteret pyrimidinderivat, fremstillingsmetode for denne og anvendelser deraf
MX2022001940A (es)	2019-08-14	2022-05-10	Incyte Corp	Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CN119930610A (zh)	2019-10-11	2025-05-06	因赛特公司	作为cdk2抑制剂的双环胺
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
JP2024523892A (ja) *	2021-06-16	2024-07-02	ブループリントメディシンズコーポレイション	Ｃｄｋ２阻害剤としての置換ピリミジニルーピラゾール
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6514977B1 (en) *	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
HUP0400639A3 (en) *	2000-12-21	2010-03-29	Vertex Pharma	Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
GB0215844D0 (en) *	2002-07-09	2002-08-14	Novartis Ag	Organic compounds
WO2005068452A1 (en) *	2004-01-09	2005-07-28	Novartis Ag	Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
CN101208093A (zh) *	2005-04-27	2008-06-25	阿斯利康(瑞典)有限公司	吡唑-嘧啶衍生物在治疗疼痛中的用途
BRPI0610184A2 (pt) *	2005-05-16	2012-09-25	Astrazeneca Ab	composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
DK1945631T3 (da) *	2005-10-28	2012-10-22	Astrazeneca Ab	4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
CA2656290A1 (en) *	2006-07-05	2008-01-10	Exelixis, Inc.	Methods of using igf1r and abl kinase modulators
CN101815712A (zh) *	2007-08-01	2010-08-25	辉瑞有限公司	吡唑化合物及其作为raf抑制剂的用途

2001
- 2001-12-05 AT AT01989898T patent/ATE407132T1/de not_active IP Right Cessation
- 2001-12-05 EP EP01989898A patent/EP1343781B1/de not_active Expired - Lifetime
- 2001-12-05 DE DE60135676T patent/DE60135676D1/de not_active Expired - Lifetime
- 2001-12-05 US US10/005,133 patent/US20020111353A1/en not_active Abandoned
- 2001-12-05 MX MXPA03005001A patent/MXPA03005001A/es active IP Right Grant
- 2001-12-05 WO PCT/US2001/046383 patent/WO2002046184A1/en not_active Ceased
- 2001-12-05 AU AU2002228783A patent/AU2002228783A1/en not_active Abandoned
- 2001-12-05 CA CA2430539A patent/CA2430539C/en not_active Expired - Fee Related
- 2001-12-05 JP JP2002547922A patent/JP4377583B2/ja not_active Expired - Lifetime
- 2001-12-05 ES ES01989898T patent/ES2307667T3/es not_active Expired - Lifetime
2009
- 2009-01-05 JP JP2009000453A patent/JP2009102377A/ja active Pending

Also Published As

Publication number	Publication date
ES2307667T3 (es)	2008-12-01
CA2430539A1 (en)	2002-06-13
WO2002046184A1 (en)	2002-06-13
AU2002228783A1 (en)	2002-06-18
DE60135676D1 (de)	2008-10-16
JP2009102377A (ja)	2009-05-14
JP4377583B2 (ja)	2009-12-02
EP1343781A1 (de)	2003-09-17
EP1343781B1 (de)	2008-09-03
JP2004518644A (ja)	2004-06-24
CA2430539C (en)	2010-07-13
US20020111353A1 (en)	2002-08-15
MXPA03005001A (es)	2003-09-05

Legal Events

Date	Code	Title	Description
2009-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE407132T1 (de)	2008-09-15	Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
WO2006083673A3 (en)	2006-12-21	Pyridine derivatives useful as inhibitors of c-jun n-terminal kinases
ATE554087T1 (de)	2012-05-15	Neue kinaseinhibitoren
DE60316810D1 (de)	2007-11-22	2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
NO20062726L (no)	2006-06-12	Nye pyridazin-3(2H)-on derivater
DE602004018780D1 (de)	2009-02-12	Inhibitoren von thienopyridin- und furopyridinkinase
ATE425160T1 (de)	2009-03-15	Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
NO20061194L (no)	2006-05-05	Mitotiske kinesininbibitorer
AU2735201A (en)	2001-07-09	Pyrimidine and triazine kinase inhibitors
ATE457311T1 (de)	2010-02-15	Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
ATE548363T1 (de)	2012-03-15	3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
NO984199L (no)	1998-11-05	Nye N-7-heterocyklylpyrrolo[2,3-D]pyridiner og deres anvendelse
ATE406351T1 (de)	2008-09-15	Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
NO20070334L (no)	2007-03-28	4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer
DE60214703D1 (de)	2006-10-26	Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
MY153898A (en)	2015-04-15	Compounds and methods for kinase modulation, and indications therefor
MXPA03010269A (es)	2004-05-05	Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
NO20045677L (no)	2005-02-28	Inhibitorer av JAK- og CDK2-proteinkinaser
NO20062174L (no)	2006-07-14	Sulfoksiminsubstituerte pyrimidiner for anvendelse som CDK og /eller VEGF-inhibitorer, fremstilling derav og deres anvendelse som legemidler
WO2003051366A3 (en)	2004-03-25	3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
DE60316013D1 (de)	2007-10-11	Heteroaryl-pyrimidinderivate als jak-inhibitoren
TN2010000087A1 (en)	2011-09-26	5-(4- haloalkoxy) phenyl pyrimidine -2- aminecompounds and compositons as kinase inhibitors
ATE450530T1 (de)	2009-12-15	Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
NO20080163L (no)	2008-03-07	Aminopyrimidiner som kinasemodulatorer
ATE528302T1 (de)	2011-10-15	3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind